Despite the impressive success of ALK inhibitors, with a median OS exceeding five years for patients receiving upfront alectinib [28], metastatic ALK+ NSCLC remains incurable, and TKI resistance eventually develops in all cases. The gene discussed is ALK; the disease is non-small cell lung carcinoma.